Global Depression Drugs Market By Drug type Analysis (Tricyclic Antidepressants, Serotonin-Norepinephrine Inhibitors, Atypical Antipsychotics, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Tetracyclic Antidepressants, Monoamine Oxidase, Inhibitors, Other), By Disease TypeAnalysis (Major Depressive Disorder, Schizophrenia, Bipolar I Disorder, Selective Serotonin Reuptake Inhibitor Induced Disorder, Other), By Distribution channel Analysis (Hospital pharmacies, Retail pharmacies, Online pharmacies, Clinics, Research centres, Other) ndustry Analysis, Trends, and Forecast 2018 – 2024

Report ID: BMRC 47 | Number of pages: 200 | Publish Date: May 2019 | Publisher: BMRC | Category: Chemicals and Materials
Global Depression Drugs Market 2018-2024
Brandessence Market Research is working on a new report title“Global Depression Drugs Market:Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Growing in geriatric population, increase in the knowledge about depression, rising number of generic drug market and declining side effects of drugs are projected to boost the growth of Global Depression Drugs Market.

Scope of Global Depression Drugs MarketReports –

 As per WHO, depression is a common mental disorder includes brain that contributes significantly to the global burden of disease. Depression is a serious mood disorder which causes a tenacious feeling of sadness and loss of interest therefore affecting daily routine activities such as sleeping, walking, talking, thinking and eating.Depression is a mental health issue. It is a condition that begins more often in initialstages of adulthood. Also it is more commonly observe in women. Though, anyone at any age may get suffer from depression.Depression affects the brain so drugs that work in the brain called ‘Antidepressant Drugs’. General antidepressants candecrease symptoms, but there are many other options to reduce the depression. Each drug used to treat depression by balancing certain chemicals in brain known as‘Neurotransmitters’. Signs and symptoms of depression differ from individual to individualon the basis of risk factors, individual thinking and lifestyle. It includes sadness, irritability, loss of attention in daily routine activities, feelings of pessimism, guilt, social withdrawal, fatigue, insomnia, loss of appetite, headache, cramps, digestive problems, weight loss or gain, restlessness and suicide attempts.Also, alcoholism and drug abuse may be the signs of depression. Likewise there are different types of depression which has distinctive characteristics such as persistent depressive disorder, perinatal depression disorder, psychotic depression, Seasonal affective disorder and bipolar depression. Depression is also classified based on its severity as mild, moderate and severe. An individual with severe depression can have suicidal thoughts and behaviors. According to 2012estimation by the WHO around 3,000 suicides take place per day, resulting in more than a million deaths each year. Depression can be recurringand can be severely debilitating. Patients with mild depression can be treated with medications but in moderate or severe depressioncases, the patient needs both medication and professional psychotherapy in the form of counseling.

The Global Depression Drugs Market is segmented on the basis of Drug type, Disease Type, Distribution channel,and Geography. On the basis of Drug type Global Depression Drugs Market is divided into Tricyclic Antidepressants, Serotonin-Norepinephrine Inhibitors, Atypical Antipsychotics, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Tetracyclic Antidepressants, Monoamine Oxidase Inhibitorsand Others.On the basis of Disease Type Global Depression Drugs Marketis divided into Major Depressive Disorder, Schizophrenia, Bipolar I Disorder, Selective Serotonin Reuptake Inhibitor Induced Disorder and other.On the basis of Distribution channel Global Depression Drugs Market is dividedintoHospital pharmacies, Retail pharmacies, Online pharmacies, Clinicsand Research centers.

The regions covered in Global Depression Drugs Marketreport are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Depression Drugs MarketReports –

Global Depression Drugs Market reports cover prominent players like Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Sebela Pharmaceutical Inc., Johnson & Johnson, Merck & Co., SK Biopharmaceuticals, Forest Laboratories, Naurex, Actavis, Bristol-Myers Squibb, Intellipharmaceutics, Lundbeck, Allergan, NHU Group,Shionogi, Kanghong Pharma, HUAHAI,Addex Therapeutics,  Alkermes, Cerecor, Dart NeuroScience,  Dr. Reddy’s Laboratories, Edgemont Pharmaceuticals, Euthymics, Fabre Kramer, Gedeon Richter, Intra-Cellular Therapies,Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Opko Health, Shire, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Torrent Pharmaceuticals and Valeant Pharmaceuticals.

 Global Depression Drugs Market Dynamics –

Increasing geriatric population globally, growing efficacy and decreasing side effectsofantidepressant drugs are the main factors that drive the Global Depression Drug Market. Also, various government initiatives in increasing awareness on depression, elevating generic drug market, are boosting theGlobal Depression Drugs Market. People transfer from rural to urban areas for job, education, etc. and their suddenly changing lifestyle is one of the key factors driving the growth of Global Depression Drugs Market. Though, lack of awareness among persons regarding depression& its growingoccurrence and threat of expiry of patents would decline the demand for Antidepressant drugs in forecast period.However, non-availability of well-developed healthcare facilities especially in rural and remote areas may decline the growth of the Global Depression Drugs Market.

Growingoccurrence of anxiety and several other depression disorders would offersome growth opportunities for the Global Depression Drugs Market in coming years. Furthermore, increasing investments in research & developments and market expansion would offer growth opportunities for the Global Depression Drugs Market players.

Global Depression Drugs MarketRegional Analysis –

Geographically, North America accounted for the largest market share of around 37.20% in 2016; due to high patient awareness levels regarding availability of various antidepressant drugs for increasing healthcare expenditure and relatively larger number of Research & Development affecting to drug manufacturing and marketing etc. These factors contribute for significant revenue generation from the region. Europe have the second largest share of the Global Depression Drugs Market in 2017, which can be recognized to the increase in research and development activities on depression drugs in the region. Asia-Pacific is to attain the fastest CAGR during the forecast period, owed to increased demand from developing countries such as China, Japan, and Australia. An initiative by the local government to reach self-sufficiency in the manufacturing of Antidepressant drugs and increasing awareness amongst consumers regarding benefits of Antidepressant drug is also likely to boost the growth of Global Depression Drugs Market in the region.

Key Benefits for Global Depression Drugs MarketReports –

Global Depression Drugs Marketreport covers in depth historical and forecast analysis.
Global Depression Drugs Marketresearch report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global Depression Drugs Marketreport helps to identify opportunities in market place.
Global Depression Drugs Marketreport covers extensive analysis of emerging trends and competitive landscape.
Global Depression Drugs MarketSegmentation–

 Global Depression Drugs Market: By Drug type Analysis

Tricyclic Antidepressants
Serotonin-Norepinephrine Inhibitors
Atypical Antipsychotics
Selective Serotonin Reuptake Inhibitors
Benzodiazepines
Tetracyclic Antidepressants
Monoamine Oxidase Inhibitors
Other
Global Depression Drugs Market: By Disease TypeAnalysis

Major Depressive Disorder
Schizophrenia
Bipolar I Disorder
Selective Serotonin Reuptake Inhibitor Induced Disorder
Other
Global Depression Drugs Market: By Distribution channel Analysis

Hospital pharmacies
Retail pharmacies
Online pharmacies
Clinics
Research centres
Other
Global Depression Drugs Market: By Regional & Country Analysis

North America
U.S.
Mexico
Canada
Europe
UK
France
Germany
Italy
Asia Pacific
China
Japan
India
Southeast Asia
Latin America
Brazil
The Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Table of Content

Chapter – Report Methodology
Research Process
Primary Research
Secondary Research
Market Size Estimates
Data Triangulation
Forecast Model
USP’s of Report
Report Description
Chapter – Global Depression Drugs Market Overview: Qualitative Analysis
Market Introduction
Executive Summary
Global Depression Drugs Market:Classification
Market Drivers
Market Restraints
Market Opportunity
Global Depression Drugs Market: Trends
Porter’s Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Consumers
Threat of New Entrants
Threat of Substitute Product and Services
Competitive Rivalry within the Industry
Market Attractiveness Analysis
Market Attractiveness Analysis by Segmentation
Market Attractiveness Analysis by Region
Chapter – Global Depression Drugs MarketOverview: Quantitative Analysis
Global Depression Drugs MarketProduction (K Unit), Market Share (%) and Growth Rate (%), 2014- 2024
Global Depression Drugs MarketConsumption (K Unit), Market Share ( %) and Growth Rate, 2014- 2024
Global Depression Drugs MarketRevenue (USD Million), Market Share (%) and Growth Rate (%), 2014- 2024
Chapter –Global Depression Drugs Market: by Drug type
Chapter – Global Depression Drugs Market : byDisease Type
Chapter – Global Depression Drugs Market : byDistribution Channel
Chapter – Global Depression Drugs Market : byManufacturer
Global Depression Drugs Market(USD Million), by Manufacturer, 2014 – 2024
Global Depression Drugs MarketProduction (K Unit), by Manufacturer, 2014 – 2024
Global Depression Drugs MarketConsumption (K Unit), Manufacturer, 2014 – 2024
Global Depression Drugs MarketShare (%), by Manufacturer, 2017
Global Depression Drugs MarketPrice (USD/Unit), by Manufacturer, 2014 – 2024
Global Depression Drugs MarketRevenue Growth Rate (%), by Manufacturer, 2014 – 2024
Merger & Acquisition
Collaborations and Partnership
New Product Launch
Chapter -Global Depression Drugs Market: Regional Analysis
North America
North America Global Depression Drugs Market Revenue (USD Million) and Growth Rate (%), 2014 – 2024.
North America Global Depression Drugs Market Revenue (USD Million) By Country, 2014 – 2024.
North America Global Depression Drugs Market Revenue Market Share (%) By Country, 2014 – 2024.
North America Global Depression Drugs Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2024.
North America Global Depression Drugs Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2024.
North AmericaGlobal Depression Drugs Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2024.
Europe
Asia Pacific
Latin America
Middle East & Africa
Chapter – Company Profiles
Actavis
Overview
Financials
Product portfolio
Global Depression Drugs MarketRevenue (USD Million), Production (K Unit), Consumption (K Unit) and Market Share (%), 2014 – 2017
Global Depression Drugs MarketShare (%), 2014 – 2017
Business strategy
Recent developments
Addex Therapeutics
Alkermes
Allergan Inc.
AstraZeneca
Bristol-Myers Squibb
Cerecor
Dart NeuroScience
Reddy’s Laboratories
Edgemont Pharmaceuticals
Eli Lilly and Company
Euthymics
Fabre Kramer
Forest Laboratories
Gedeon Richter
HUAHAI
Intellipharmaceutics
Intra-Cellular Therapies
Janssen Pharmaceuticals
Johnson & Johnson
Kanghong Pharma
Lundbeck
Lupin
Luye Pharma
Merck & Co.
MSI Methylation Sciences
Naurex
NHU Group
Novartis AG, GlaxoSmithKline
Opko Health
Otsuka Pharmaceutical Co. Ltd.
Pfizer Inc.
Sebela Pharmaceutical Inc.
Shionogi
Shire
SK Biopharmaceuticals
Somerset Pharmaceuticals
Sun Pharmaceutical
Sunovion Pharmaceuticals
Takeda Pharmaceutical Company Ltd
Torrent Pharmaceuticals
Valeant Pharmaceuticals
Others
Chapter – Market Research and Findings
This free Sample Report is purely a representation of our full report, for evaluating the market scope/data and make informed purchase decisions.